Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 30,159	$ 35,627
Marketable securities, short-term	118,989	135,930
Prepaid expenses and other current assets	5,799	6,749
Total current assets	154,947	178,306
Marketable securities, long-term	48,795	59,968
Restricted cash	232	232
Other assets, long-term	504	486
Total assets	204,478	238,992
Current liabilities
Accounts payable	1,056	5,648
Accrued clinical trial expenses	11,548	15,344
Accrued expenses and other current liabilities	6,711	6,615
Total current liabilities	19,315	27,607
Debt, long-term	29,528	29,419
Other liabilities, long-term	114	150
Total liabilities	48,957	57,176
Commitments and contingencies (Note 10)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2025 and December 31, 2024	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 60,573,425 and 60,094,083 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively	6	6
Additional paid-in capital	509,423	506,985
Accumulated deficit	(353,923)	(325,127)
Accumulated other comprehensive income (loss)	15	(48)
Total stockholders’ equity	155,521	181,816
Total liabilities and stockholders’ equity	$ 204,478	$ 238,992